Wuhan YZY Biopharma H1 FY26 net loss narrows to RMB 6.26 million; revenue falls 10.87% to RMB 33.14 million

• Wuhan Yzy Biopharma posted revenue of RMB 33.14 million; loss narrowed to RMB 6.26 million, EPS improved to RMB -0.03.
• Gross profit rose to RMB 25.26 million as cost of revenue fell to RMB 7.89 million; R&D expense dropped to RMB 17.58 million.
• Other income slid to RMB 2.89 million on lower government grants; other gains and losses swung to a RMB 1.33 million loss.
• M701 malignant ascites NDA was accepted by China’s NMPA in May 2026; Phase III results were selected for an ASCO 2026 oral presentation.
• M701 malignant pleural effusion Phase Ib/II in China enrolled 92 patients; cash and cash equivalents fell to RMB 76 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12304329), on August 28, 2026, and is solely responsible for the information contained therein.